Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology

Cardiovascular Research

Volumn 77, Issue 2, 2008, Pages 265-273

  Periasamy, Muthu ^a   Bhupathy, Poornima ^a   Babu, Gopal J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Atria; Calcium; Cardiac contractility; Phospholamban; Sarcolipin; SR Ca2+ ATPase; Ventricle

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); MUSCLE PROTEIN; PHOSPHOLAMBAN; SARCOLIPIN; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CYTOSOL; ENERGY TRANSFER; GENE TRANSFER; HEART ATRIUM CONTRACTION; HEART DEVELOPMENT; HEART DISEASE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HOMEOSTASIS; HUMAN; MOLECULAR WEIGHT; MUSCLE RELAXATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; ENERGY METABOLISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE THERAPY; HUMANS; MUSCLE PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEOLIPIDS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; THYROXINE;

EID: 38849115741     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm056     Document Type: Review

References (118)

1. Fabiato A, Fabiato F. Calcium and cardiac excitation-contraction coupling. Annu Rev Physiol 1979;41:473-484.
2. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
3. Lederer WJ, Berlin JR, Cohen NM, Hadley RW, Bers DM, Cannell MB. Excitation-contraction coupling in heart cells. Roles of the sodium-calcium exchange, the calcium current, and the sarcoplasmic reticulum. Ann N Y Acad Sci 1990;588:190-206.
4. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 2004;37:417-429.
5. Periasamy M, Huke S. SERCA pump level is a critical determinant of Ca(2+) homeostasis and cardiac contractility. J Mol Cell Cardiol 2001;33:1053-1063.
6. Mork HK, Sjaastad I, Sande JB, Periasamy M, Sejersted OM, Louch WE. Increased cardiomyocyte function and Ca(2+) transients in mice during early congestive heart failure. J Mol Cell Cardiol 2007;43:177-186.
7. Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 1998;78:921-947.
8. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566-577.
9. MacLennan DH, Asahi M, Tupling AR. The regulation of SERCA-type pumps by phospholamban and sarcolipin. Ann N Y Acad Sci 2003;986:472-480.
10. MacLennan DH, Abu-Abed M, Kang C. Structure-function relationships in Ca(2+) cycling proteins. J Mol Cell Cardiol 2002;34:897-918.
11. Bhupathy P, Babu GJ, Periasamy M. Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca(2+) ATPase. J Mol Cell Cardiol 2007;42:903-911.
12. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000;32:2131-2139.
13. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med 2000;32:572-578.
14. Vangheluwe P, Schuermans M, Zador E, Waelkens E, Raeymaekers L, Wuytack F. Sarcolipin and phospholamban mRNA and protein expression in cardiac and skeletal muscle of different species. Biochem J 2005;389:151-159.
15. 2+ adenosine triphosphatase by phospholamban and sarcolipin: implication for cardiac hypertrophy and failure. Trends Cardiovasc Med 2003;13:152-157.
16. 2+-ATPase. J Biol Chem 1998;273:12360-12369.
17. 2+ affinity in cardiac function. Biochim Biophys Acta 2006;1763:1216-1228.
18. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-469.
19. Zarain-Herzberg A, MacLennan DH, Periasamy M. Characterization of rabbit cardiac sarco(endo)plasmic reticulum Ca2(+)-ATPase gene. J Biol Chem 1990;265:4670-4677.
20. Arai M, Otsu K, MacLennan DH, Periasamy M. Regulation of sarcoplasmic reticulum gene expression during cardiac and skeletal muscle development. Am J Physiol 1992;262:C614-C620.
21. Anger M, Samuel JL, Marotte F, Wuytack F, Rappaport L, Lompre AM. In situ mRNA distribution of sarco(endo)plasmic reticulum Ca(2+)-ATPase isoforms during ontogeny in the rat. J Mol Cell Cardiol 1994;26:539-550.
22. Lompre AM, Anger M, Levitsky D. Sarco(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression. J Mol Cell Cardiol 1994;26:1109-1121.
23. Lompre AM, Lambert F, Lakatta EG, Schwartz K. Expression of sarcoplasmic reticulum Ca(2+)-ATPase and calsequestrin genes in rat heart during ontogenic development and aging. Circ Res 1991;69:1380-1388.
24. Reed TD, Babu GJ, Ji Y, Zilberman A, Ver Heyen M, Wuytack F et al. The expression of SR calcium transport ATPase and the Na(+)/Ca(2+) Exchanger are antithetically regulated during mouse cardiac development and in Hypo/hyperthyroidism. J Mol Cell Cardiol 2000;32:453-464.
25. Gombosova I, Boknik P, Kirchhefer U, Knapp J, Luss H, Muller FU et al. Postnatal changes in contractile time parameters, calcium regulatory proteins, and phosphatases. Am J Physiol 1998;274:H2123-H2132.
26. Luss I, Boknik P, Jones LR, Kirchhefer U, Knapp J, Linck B et al. Expression of cardiac calcium regulatory proteins in atrium v ventricle in different species. J Mol Cell Cardiol 1999;31:1299-1314.
27. Koss KL, Ponniah S, Jones WK, Grupp IL, Kranias EG. Differential phospholamban gene expression in murine cardiac compartments. Molecular and physiological analyses. Circ Res 1995;77:342-353.
28. Minajeva A, Kaasik A, Paju K, Seppet E, Lompre AM, Veksler V et al. Sarcoplasmic reticulum function in determining atrioventricular contractile differences in rat heart. Am J Physiol 1997;273:H2498- H2507.
29. Jiang MT, Moffat MP, Narayanan N. Age-related alterations in the phosphorylation of sarcoplasmic reticulum and myofibrillar proteins and diminished contractile response to isoproterenol in intact rat ventricle. Circ Res 1993;72:102-111.
30. Lakatta EG. Myocardial adaptations in advanced age. Basic Res Cardiol 1993;88(Suppl. 2):125-133.
31. Cain BS, Meldrum DR, Joo KS, Wang JF, Meng X, Cleveland JC Jr et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998;32:458-467.
32. Schmidt U, del Monte F, Miyamoto MI, Matsui T, Gwathmey JK, Rosenzweig A et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation 2000;101:790-796.
33. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res 1994;74:555-564.
34. Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M. Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins. Circ Res 1991;69:266-276.
35. 2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci USA 1989;86:2966-2970.
36. Kiss E, Jakab G, Kranias EG, Edes I. Thyroid hormone-induced alterations in phospholamban protein expression. Regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation. Circ Res 1994;75:245-251.
37. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 1999;99:641-648.
38. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-442.
39. Pieske B, Maier LS, Bers DM, Hasenfuss G. Ca2+ handling and sarcoplasmic reticulum Ca2+ content in isolated failing and nonfailing human myocardium. Circ Res 1999;85:38-46.
40. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-784.
41. O'Rourke B, Kass DA, Tomaselli GF, Kaab S, Tunin R, Marban E. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res 1999;84:562-570.
42. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998;37:279-289.
43. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol 1997;92(Suppl. 1):87-93.
44. Movsesian MA, Karimi M, Green K, Jones LR. Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994;90:653-657.
45. Munch G, Bolck B, Hoischen S, Brixius K, Bloch W, Reuter H et al. Unchanged protein expression of sarcoplasmic reticulum Ca2+-ATPase, phospholamban, and calsequestrin in terminally failing human myocardium. J Mol Med 1998;76:434-441.
46. del Monte F, Hajjar RJ, Harding SE. Overwhelming evidence of the beneficial effects of SERCA gene transfer in heart failure. Circ Res 2001;88:E66-E67.
47. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999;100:2308-2311.
48. Maack C, O'Rourke B. Excitation-contraction coupling and mitochondrial energetics. Basic Res Cardiol 2007;102:369-392.
49. Meyer M, Keweloh B, Guth K, Holmes JW, Pieske B, Lehnart SE et al. Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations. J Mol Cell Cardiol 1998;30:1459-1470.
50. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004;95:135-145.
51. 2+ handling contributes to decreased contractile reserve in rat hearts. Am J Physiol 1998;275:H2064-H2071.
52. Neubauer S, Horn M, Naumann A, Tian R, Hu K, Laser M et al. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 1995;95:1092-1100.
53. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000;97:793-798.
54. del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001;104:1424-1429.
55. 2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res 1998;83:1205-1214.
56. Loukianov E, Ji Y, Baker DL, Reed T, Babu J, Loukianova T et al. Sarco(endo)plasmic reticulum Ca2+ ATPase isoforms and their role in muscle physiology and pathology. Ann N Y Acad Sci 1998;853:251-259.
57. 2+ handling in normal and diabetic rat hearts. FASEB J 2002;16:1657-1659.
58. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 1997;100:380-389.
59. 2+-ATPase. Circ Res 1998;83:889-897.
60. 2+ homeostasis and cardiomyocyte function. J Biol Chem 2000;275:38073-38080.
61. 2+-ATPase isoform 2 (SERCA2) gene. J Biol Chem 1999;274:2556-2562.
62. 2+ pumps revealed by analysis of null mutants. Ann N Y Acad Sci 2003;986:453-460.
63. Schultz J, Glascock BJ, Witt SA, Nieman ML, Nattamai KJ, Liu LH et al. Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am J Physiol Heart Circ Physiol 2004;286:H1146-H1153.
64. Ver Heyen M, Heymans S, Antoons G, Reed T, Periasamy M, Awede B et al. Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 2001;89:838-846.
65. Tada M. Molecular structure and function of phospholamban in regulating the calcium pump from sarcoplasmic reticulum. Ann N Y Acad Sci 1992;671:92-102. discussion 102-103.
66. Tada M, Inui M. Regulation of calcium transport by the ATPase-phospholamban system. J Mol Cell Cardiol 1983;15:565-575.
67. Tada M, Ohmori F, Kinoshita N, Abe H. Cyclic AMP regulation of active calcium transport across membranes of sarcoplasmic reticulum: role of the 22,000-dalton protein phospholamban. Adv Cyclic Nucleotide Res 1978;9:355-369.
68. Kadambi VJ, Kranias EG. Phospholamban: a protein coming of age. Biochem Biophys Res Commun 1997;239:1-5.
69. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996;79:1059-1063.
70. Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, Vittone L, Kranias E. Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc Res 2005;68:366-375.
71. Carr AN, Kranias EG. Thyroid hormone regulation of calcium cycling proteins. Thyroid 2002;12:453-457.
72. 2+ ATPase and decreasing phospholamban expression. J Mol Cell Cardiol 1994;26:1145-1154.
73. Zhong Y, Reiser PJ, Matlib MA. Gender differences in myosin heavy chain-beta and phosphorylated phospholamban in diabetic rat hearts. Am J Physiol Heart Circ Physiol 2003;285:H2688-H2693.
74. Boknik P, Heinroth-Hoffmann I, Kirchhefer U, Knapp J, Linck B, Luss H et al. Enhanced protein phosphorylation in hypertensive hypertrophy. Cardiovasc Res 2001;51:717-728.
75. 2+ ATPase type 2 (SERCA 2) in cardiac sarcoplasmic reticulum from rabbits with heart failure. Cardiovasc Res 1999;41:135-146.
76. Mills GD, Kubo H, Harris DM, Berretta RM, Piacentino V 3rd, Houser SR. Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol 2006;291:H61-H70.
77. Sande JB, Sjaastad I, Hoen IB, Bokenes J, Tonnessen T, Holt E et al. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc Res 2002;53:382-391.
78. Schmidt U, Hajjar RJ, Kim CS, Lebeche D, Doye AA, Gwathmey JK. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol 1999;277:H474-H480.
79. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E. Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 1999;31:479-491.
80. Brixius K, Wollmer A, Bolck B, Mehlhorn U, Schwinger RH. Ser16-, but not Thr17-phosphorylation of phospholamban influences frequency-dependent force generation in human myocardium. Pflugers Arch 2003;447:150-157.
81. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 2004;61:87-93.
82. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994;75:401-409.
83. 2+ transport. Circ Res 2003;92:769-776.
84. Haghighi K, Schmidt AG, Hoit BD, Brittsan AG, Yatani A, Lester JW et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 2001;276:24145- 24152.
85. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW II, Walsh RA et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996;97:533-539.
86. Kiriazis H, Kranias EG. Genetically engineered models with alterations in cardiac membrane calcium-handling proteins. Annu Rev Physiol 2000;62:321-351.
87. Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA 2006;103:1388-1393.
88. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003;111:869-876.
89. Voss J, Jones LR, Thomas DD. The physical mechanism of calcium pump regulation in the heart. Biophys J 1994;67:190-196.
90. Cornea RL, Jones LR, Autry JM, Thomas DD. Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers. Biochemistry 1997;36:2960-2967.
91. Zvaritch E, Backx PH, Jirik F, Kimura Y, de Leon S, Schmidt AG et al. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J Biol Chem 2000;275:14985-14991.
92. Kimura Y, Kurzydlowski K, Tada M, MacLennan DH. Phospholamban inhibitory function is activated by depolymerization. J Biol Chem 1997;272:15061-15064.
93. Zhai J, Schmidt AG, Hoit BD, Kimura Y, MacLennan DH, Kranias EG. Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo. J Biol Chem 2000;275:10538-10544.
94. Odermatt A, Taschner PE, Scherer SW, Beatty B, Khanna VK, Cornblath DR et al. Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: absence of structural mutations in five patients with Brody disease. Genomics 1997;45:541-553.
95. Babu GJ, Bhupathy P, Carnes CA, Billman GE, Periasamy M. Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology. J Mol Cell Cardiol 2007;43:215-222.
96. Minamisawa S, Wang Y, Chen J, Ishikawa Y, Chien KR, Matsuoka R. Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling. J Biol Chem 2003;278:9570-9575.
97. Buffy JJ, Buck-Koehntop BA, Porcelli F, Traaseth NJ, Thomas DD, Veglia G. Defining the intramembrane binding mechanism of sarcolipin to calcium ATPase using solution NMR spectroscopy. J Mol Biol 2006;358:420-429.
98. Buffy JJ, Traaseth NJ, Mascioni A, Gor'kov PL, Chekmenev EY, Brey WW et al. Two-dimensional solid-state NMR reveals two topologies of sarcolipin in oriented lipid bilayers. Biochemistry 2006;45:10939- 10946.
99. Hellstern S, Pegoraro S, Karim CB, Lustig A, Thomas DD, Moroder L et al. Sarcolipin, the shorter homologue of phospholamban, forms oligomeric structures in detergent micelles and in liposomes. J Biol Chem 2001;276:30845-30852.
100. Mascioni A, Karim C, Barany G, Thomas DD, Veglia G. Structure and orientation of sarcolipin in lipid environments. Biochemistry 2002;41:475-482.
101. 2+-ATPase (SERCA) by binding to transmembrane helices alone or in association with phospholamban. Proc Natl Acad Sci USA 2003;100:5040-5045.
102. Babu GJ, Bhupathy P, Petrashevskaya NN, Wang H, Raman S, Wheeler D et al. Targeted overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and cardiac contractility. J Biol Chem 2006;281:3972-3979.
103. Babu GJ, Zheng Z, Natarajan P, Wheeler D, Janssen PM, Periasamy M. Overexpression of sarcolipin decreases myocyte contractility and calcium transient. Cardiovasc Res 2005;65:177-186.
104. 2+ ATPase (SERCA2a) activity and impairs cardiac function in mice. Proc Natl Acad Sci USA 2004;101:9199-9204.
105. 2+-ATPases (SERCAs). J Biol Chem 2002;277:26725-26728.
106. Gramolini AO, Kislinger T, Asahi M, Li W, Emili A, MacLennan DH. Sarcolipin retention in the endoplasmic reticulum depends on its C-terminal RSYQY sequence and its interaction with sarco(endo)plasmic Ca(2+)-ATPases. Proc Natl Acad Sci USA 2004;101:16807-16812.
107. Boknik P, Unkel C, Kirchhefer U, Kleideiter U, Klein-Wiele O, Knapp J et al. Regional expression of phospholamban in the human heart. Cardiovasc Res 1999;43:67-76.
108. Kaasik A, Paju K, Minajeva A, Ohisalo J. Decreased expression of phospholamban is not associated with lower beta-adrenergic activation in rat atria. Mol Cell Biochem 2001;223:109-115.
109. Gramolini AO, Trivieri MG, Oudit GY, Kislinger T, Li W, Patel MM et al. Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proc Natl Acad Sci USA 2006;103:2446-2451.
110. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998;95:5251-5256.
111. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000;86:616-621.
112. Hajjar RJ. The promise of gene therapy as a therapeutic modality in heart failure. J Med Liban 2000;48:86-88.
113. del Monte F, Kizana E, Tabchy A, Hajjar RJ. Targeted gene transfer in heart failure: implications for novel gene identification. Curr Opin Mol Ther 2004;6:381-394.
114. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004;101:5622-5627.
115. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999;99:313-322.
116. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002;105:904-907.
117. Hoshijima M, Ikeda Y, Iwanaga Y, Minamisawa S, Date MO, Gu Y et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002;8:864-871.
118. Babu GJ, Bhupathy P, Timofeyev V, Petrashevskaya NN, Reiser PJ, Chiamvimonvat N et al. Ablation of sarcolipin enhances sarcoplasmic reticulum calcium transport and atrial contractility. Proc Natl Acad Sci USA 2007;104:17867-17872.